Cd Private Equity Fund Iii logo
CD3

Cd Private Equity Fund Iii

Short interest
0.00%
as of 12 Dec 2022
Reported shorts
1.4K
Shares on issue
72.028M

Cd Private Equity Fund Iii (CD3) Short Interest

Cd Private Equity Fund Iii (ASX:CD3) had 0.00% of shares reported as short positions as of 12 Dec 2022, representing 1,378 shares. Source: ASIC short position report (T+4 delay).

Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.

Price & short interest

About Cd Private Equity Fund Iii

Cd Private Equity Fund Iii (CD3) is an ASX-listed Managed Investment Scheme providing investors with exposure to a portfolio of small-to-mid sized private investment funds and privately held companies, primarily in the US. The fund replicates the long-term private equity investment strategy of Cordish Private Ventures, offering side-by-side investment opportunities with the Cordish Family. Its objective is to achieve capital growth over a five to ten-year horizon by focusing on niche investment opportunities and operating businesses with proven cash flows.

Company profile →

Cd Private Equity Fund Iii (ASX:CD3) has 0.00% of its shares on issue reported as short positions as of 12 Dec 2022, or about 1,378 shares. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Short interest

History & FAQ →

Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.

Strategy fit

How each stock picker strategy reads CD3 today

Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →

CD3 fundamentals

In the year to 31 Mar 2026, Cd Private Equity Fund Iii (ASX:CD3) recorded revenue of −A$696.7K and a net loss after tax of A$9.0M. A year earlier it recorded revenue of −A$171.2K and net profit after tax of A$18.6M. Return on equity −7.2% (FY). Figures are in AUD, the company's reporting currency; source: Yahoo Finance, as at 14 Oct 2026.

Full statements, ratios and filings are on the Financials tab. Not financial advice.

Full financials →

Company details

address

Level 44, 101 Collins Street, MELBOURNE, VIC, AUSTRALIA, 3000

Be the first to discuss CD3

Start a research thread or post the first pulse update